Sorafenib + FOLFIRI

Sorafenib + FOLFIRI is a combination regimen used in oncology clinical trials, particularly for advanced gastrointestinal malignancies such as colorectal cancer. Sorafenib is an oral small molecule multikinase inhibitor that targets several serine/threonine and tyrosine kinases, including all vascular endothelial growth factor receptors (VEGFR), Raf kinases, platelet-derived growth factor receptor beta (PDGFR-β), and fibroblast growth factor receptor 1 (FGFR1). This results in inhibition of tumor cell proliferation and angiogenesis. FOLFIRI is a chemotherapy regimen consisting of folinic acid (leucovorin), fluorouracil (5-FU), and irinotecan. Fluorouracil acts as an antimetabolite inhibiting DNA synthesis; irinotecan inhibits topoisomerase I, preventing DNA replication; folinic acid enhances the effect of fluorouracil. The combination aims to provide both cytotoxic effects from chemotherapy and antiangiogenic/antiproliferative effects from sorafenib[1][4][6][8].

Brand names

Nexavar

Other names

sorafenibfolinic acid, fluorouracil and irinotecanirinotecan de Gramontirinotecan modified de Gramont